Search results
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 16 hours agoPfizer is competing against GSK's Arexvy, which hit the market about the same time in 2023. Moderna...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 10 hours agoBut longer-term sales are expected to be below 2024 estimates. It will be key to watch how the...
Is Pfizer the Best Dividend Stock for You?
Motley Fool via Yahoo Finance· 7 days agoAs a result, share prices have fallen and the stock trades near its lowest level in years. The falling share price has pushed the stock's dividend...pain...
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Motley Fool via Yahoo Finance· 3 days agoBut investors will need to be patient. The company's transition will take time Pfizer is facing some...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 9 hours agoBoth measures beat expectations. Earnings turned around from a year-earlier loss, while sales...
California State Teachers Retirement System Increases Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 5 days agoCalifornia State Teachers Retirement System grew its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 1.5% during the fourth quarter, according to its most recent 13F filing ...
Should You Pick Moderna Stock At $150 After 25% Gains In A Month?
Forbes· 23 hours agoModerna has a couple of factors to back its strong run. Firstly, the U.S. FDA recently approved...
Is Moderna Stock a Buy Now That It's a 2-Product Company?
The Motley Fool via AOL· 5 days agoThe Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. *Stock Advisor returns as of June 3, 2024 Cory Renauer has no position in any of the stocks mentioned. The ...
The Push to Get More People Into Long COVID Studies
Medscape· 4 days agoWhen Ezra Spier was diagnosed with long COVID in late 2022, his main symptom, postexertional malaise, caused fatigue so severe that it forced him to quit...
Blue-Chip Blunders: 7 Stocks to Sell as Management Missteps Mount
InvestorPlace· 6 days agoWhile macro-related issues are a factor, it’s company-specific issues that play a more significant...
